Anbio Biotechnology (NNNN)
Anbio Biotechnology will go public soon, but the exact IPO date is still unknown.
IPO Price Range
$5.00 - $6.00
Shares Offered
1,600,000
Deal Size
$8.80M
Company Description
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products.
At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.
Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications.
Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains.
These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
Anbio Biotechnology
| Country | Germany |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Michael Lau |
Contact Details
Address: Wilhelm Gutbrod Str 21B, 60437 Frankfurt am Main Germany | |
| Phone | +49 16 0962 47281 |
Stock Details
| Ticker Symbol | NNNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001982708 |
Key Executives
| Name | Position |
|---|---|
| Michael Lau | Chief Executive Officer |
| Suki Song | Chief Financial Officer |
| Chris Tian | Chief Business Officer |
| Cany Xu | Director |
| Nancy Hartzler | Independent Director (Appointee), Chair of Compensation Committee |
| Kenneth Li | Independent Director (Appointee), Chair of Audit Committee |
| David Hsu | Independent Director (Appointee), Chair of Nominating Committee |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | F-1 | Registration statement for certain foreign private issuers |
| Dec 11, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Nov 18, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 1, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 10, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Mar 11, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Dec 27, 2023 | DRS | [Cover] Draft Registration Statement |